help button home button Am J Pathol ASIP WHAT IS IT?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, M. E.
Right arrow Articles by Raine, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, M. E.
Right arrow Articles by Raine, C. S.
(American Journal of Pathology. 1999;155:1147-1161.)
© 1999 American Society for Investigative Pathology

Regular Articles

Age Dependence of Clinical and Pathological Manifestations of Autoimmune Demyelination

Implications for Multiple Sclerosis

Mary E. Smith*{dagger}, Nancy L. Eller*{ddagger}, Henry F. McFarland*, Michael K. Racke*§ and Cedric S. Raine

From the Neuroimmunology Branch,*
National Institute of Neurological Disorders and Stroke, Division of Acquired Immunodeficiency Syndrome,{dagger}
National Institute of Allergy and Infectious Diseases, Center for Biologics Evaluation and Research,{ddagger}
Food and Drug Administration, Bethesda, Maryland; the Department of Neurology,§
Washington University School of Medicine, St. Louis, Missouri; and the Departments of Pathology, Neurology, and Neuroscience,
Albert Einstein College of Medicine, Bronx, New York

A prominent feature of the clinical spectrum of multiple sclerosis (MS) is its high incidence of onset in the third decade of life and the relative rarity of clinical manifestations during childhood and adolescence, features suggestive of age-related restriction of clinical expression. Experimental allergic encephalomyelitis (EAE), a model of central nervous system (CNS) autoimmune demyelination with many similarities to MS, has a uniform rapid onset and a high incidence of clinical and pathological disease in adult (mature) animals. Like MS, EAE is most commonly seen and studied in female adults. In this study, age-related resistance to clinical EAE has been examined with the adoptive transfer model of EAE in SJL mice that received myelin basic protein-sensitized cells from animals 10 days (sucklings) to 12 weeks (young adults) of age. A variable delay before expression of clinical EAE was observed between the different age groups. The preclinical period was longest in the younger (<14 days of age) animals, and shortest in animals 6 to 8 weeks old at time of transfer. Young animals initially resistant to EAE eventually expressed well-developed clinical signs by 6 to 7 weeks of age. This was followed by a remitting, relapsing clinical course. For each age at time of sensitization, increased susceptibility of females compared to males was observed. Examination of the CNS of younger animal groups during the preclinical period showed lesions of acute EAE. Older age groups developed onset of signs coincident with acute CNS lesions. This age-related resistance to clinical EAE in developing mice is reminiscent of an age-related characteristic of MS previously difficult to study in vivo. The associated subclinical CNS pathology and age-related immune functions found in young animals may be relevant to the increasing clinical expression of MS with maturation, and may allow study of factors associated with the known occasional poor correlation of CNS inflammation and demyelination and clinical changes in this disease.




This article has been cited by other articles:


Home page
 BrainHome page
C. Confavreux and S. Vukusic
Age at disability milestones in multiple sclerosis
Brain, March 1, 2006; 129(3): 595 - 605.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Jun, W. Gilmore, G. Callis, A. Rynda, A. Haddad, and D. W. Pascual
A Live Diarrheal Vaccine Imprints a Th2 Cell Bias and Acts as an Anti-Inflammatory Vaccine
J. Immunol., November 15, 2005; 175(10): 6733 - 6740.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. Teuscher, J. Y. Bunn, P. D. Fillmore, R. J. Butterfield, J. F. Zachary, and E. P. Blankenhorn
Gender, Age, and Season at Immunization Uniquely Influence the Genetic Control of Susceptibility to Histopathological Lesions and Clinical Signs of Experimental Allergic Encephalomyelitis: Implications for the Genetics of Multiple Sclerosis
Am. J. Pathol., November 1, 2004; 165(5): 1593 - 1602.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. H. Weerth, H. Rus, M. L. Shin, and C. S. Raine
Complement C5 in Experimental Autoimmune Encephalomyelitis (EAE) Facilitates Remyelination and Prevents Gliosis
Am. J. Pathol., September 1, 2003; 163(3): 1069 - 1080.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. Gaupp, D. Pitt, W. A. Kuziel, B. Cannella, and C. S. Raine
Experimental Autoimmune Encephalomyelitis (EAE) in CCR2-/- Mice: Susceptibility in Multiple Strains
Am. J. Pathol., January 1, 2003; 162(1): 139 - 150.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Filippi, J. S. Wolinsky, M.P. S. PhD, and G. Comi
Enhancement frequency decreases with increasing age in relapsing-remitting multiple sclerosis
Neurology, February 13, 2001; 56(3): 422 - 423.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Society for Investigative Pathology.